RESUMEN
OBJECTIVE: This study aimed to improve the efficiency of pharmacotherapy for CNS diseases by optimizing the ability of drug molecules to penetrate the Blood-Brain Barrier (BBB). METHODS: We established qualitative and quantitative databases of the ADME properties of drugs and derived characteristic features of compounds with efficient BBB penetration. Using these insights, we developed four machine learning models to predict a drug's BBB permeability by assessing ADME properties and molecular topology. We then validated the models using the B3DB database. For acyclovir and ceftriaxone, we modified the Hydrogen Bond Donors and Acceptors, and evaluated the BBB permeability using the predictive model. RESULTS: The machine learning models performed well in predicting BBB permeability on both internal and external validation sets. Reducing the number of Hydrogen Bond Donors and Acceptors generally improves BBB permeability. Modification only enhanced BBB penetration in the case of acyclovir and not ceftriaxone. CONCLUSIONS: The machine learning models developed can accurately predict BBB permeability, and many drug molecules are likely to have increased BBB penetration if the number of Hydrogen Bond Donors and Acceptors are reduced. These findings suggest that molecular modifications can enhance the efficacy of CNS drugs and provide practical strategies for drug design and development. This is particularly relevant for improving drug penetration of the BBB.
Asunto(s)
Aciclovir , Barrera Hematoencefálica , Aprendizaje Automático , Permeabilidad , Barrera Hematoencefálica/metabolismo , Humanos , Aciclovir/farmacocinética , Enlace de Hidrógeno , Ceftriaxona/farmacocinética , Fármacos del Sistema Nervioso Central/farmacocinética , Fármacos del Sistema Nervioso Central/química , Fármacos del Sistema Nervioso Central/metabolismo , Diseño de FármacosRESUMEN
One challenge in central nervous system (CNS) drug discovery has been ensuring the blood-brain barrier (BBB) penetration of compounds at an efficacious concentration that provides suitable safety margins for clinical investigation. Research providing for the accurate prediction of brain penetration of compounds during preclinical discovery is important to a CNS program. In the BBB, P-glycoprotein (P-gp) (ABCB1) and breast cancer resistance protein (BCRP) (ABCG2) transporters have been demonstrated to play a major role in the active efflux of endogenous compounds and xenobiotics out of the brain microvessel cells and back to the systemic circulation. In the past 10 years, there has been significant technological improvement in the sensitivity of quantitative proteomics methods, in vivo imaging, in vitro methods of organoid and microphysiological systems, as well as in silico quantitative physiological based pharmacokinetic and systems pharmacology models. Scientists continually leverage these advancements to interrogate the distribution of compounds in the CNS which may also show signals of substrate specificity of P-gp and/or BCRP. These methods have shown promise toward predicting and quantifying the unbound concentration(s) within the brain relevant for efficacy or safety. In this review, the authors have summarized the in vivo, in vitro, and proteomics advancements toward understanding the contribution of P-gp and/or BCRP in restricting the entry of compounds to the CNS of either healthy or special populations. Special emphasis has been provided on recent investigations on the application of a proteomics-informed approach to predict steady-state drug concentrations in the brain. Moreover, future perspectives regarding the role of these transporters in newer modalities are discussed.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP , Neoplasias de la Mama , Humanos , Femenino , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/metabolismo , Transportadoras de Casetes de Unión a ATP/metabolismo , Proteínas de Neoplasias/metabolismo , Subfamilia B de Transportador de Casetes de Unión a ATP , Encéfalo/metabolismo , Barrera Hematoencefálica/metabolismo , Fármacos del Sistema Nervioso Central/metabolismo , Neoplasias de la Mama/metabolismoRESUMEN
Central nervous system (CNS) diseases are among the most difficult to treat, mainly because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach the brain at concentrations adequate to exert a pharmacological activity. The obstacle posed by the BBB has led to the in-depth study of strategies allowing the brain delivery of CNS-active drugs. Among the most promising strategies is the use of peptides addressed to the BBB. Peptides are versatile molecules that can be used to decorate nanoparticles or can be conjugated to drugs, with either a stable link or as pro-drugs. They have been used to deliver to the brain both small molecules and proteins, with applications in diverse therapeutic areas such as brain cancers, neurodegenerative diseases and imaging. Peptides can be generally classified as receptor-targeted, recognizing membrane proteins expressed by the BBB microvessels (e.g., Angiopep2, CDX, and iRGD), "cell-penetrating peptides" (CPPs; e.g. TAT47-57, SynB1/3, and Penetratin), undergoing transcytosis through unspecific mechanisms, or those exploiting a mixed approach. The advantages of peptides have been extensively pointed out, but so far few studies have focused on the potential negative aspects. Indeed, despite having a generally good safety profile, some peptide conjugates may display toxicological characteristics distinct from those of the peptide itself, causing for instance antigenicity, cardiovascular alterations or hemolysis. Other shortcomings are the often brief lifetime in vivo, caused by the presence of peptidases, the vulnerability to endosomal/lysosomal degradation, and the frequently still insufficient attainable increase of brain drug levels, which remain below the therapeutically useful concentrations. The aim of this review is to analyze not only the successful and promising aspects of the use of peptides in brain targeting but also the problems posed by this strategy for drug delivery.
Asunto(s)
Encéfalo , Nanopartículas , Encéfalo/metabolismo , Barrera Hematoencefálica/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Transcitosis , Nanopartículas/química , Fármacos del Sistema Nervioso Central/metabolismo , Preparaciones Farmacéuticas/metabolismoRESUMEN
Atypical responses to sensory stimuli are considered as a core aspect and early life marker of autism spectrum disorders (ASD). Although recent findings performed in mouse ASD genetic models report sensory deficits, these were explored exclusively during juvenile or adult period. Whether sensory dysfunctions might be present at the early life stage and rescued by therapeutic strategy are fairly uninvestigated. Here we found that under cool environment neonatal mice lacking the autism-associated gene Magel2 present pup calls hypo-reactivity and are retrieved with delay by their wild-type dam. This neonatal atypical sensory reactivity to cool stimuli was not associated with autonomic thermoregulatory alteration but with a deficit of the oxytocinergic system. Indeed, we show in control neonates that pharmacogenetic inactivation of hypothalamic oxytocin neurons mimicked atypical thermosensory reactivity found in Magel2 mutants. Furthermore, pharmacological intranasal administration of oxytocin to Magel2 neonates was able to rescue both the atypical thermosensory response and the maternal pup retrieval. This preclinical study establishes for the first-time early life impairments in thermosensory integration and suggest a therapeutic potential benefit of intranasal oxytocin treatment on neonatal atypical sensory reactivity for autism.
Asunto(s)
Trastorno Autístico , Hipoestesia , Conducta Materna , Oxitocina , Proteínas , Administración Intranasal , Factores de Edad , Animales , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/metabolismo , Trastorno del Espectro Autista/complicaciones , Trastorno Autístico/complicaciones , Trastorno Autístico/genética , Trastorno Autístico/metabolismo , Fármacos del Sistema Nervioso Central/administración & dosificación , Fármacos del Sistema Nervioso Central/metabolismo , Femenino , Hipoestesia/etiología , Hipoestesia/genética , Hipoestesia/metabolismo , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Conducta Materna/fisiología , Ratones , Oxitocina/administración & dosificación , Oxitocina/metabolismo , Proteínas/genética , Proteínas/metabolismo , Conducta SocialRESUMEN
The brain capillary endothelium serves both as an exchange site for gases and solutes between blood and brain and as a protective fence against neurotoxic compounds from the blood. While this "blood-brain barrier" (BBB) function protects the fragile environment in the brain, it also poses a tremendous challenge for the delivery of drug compounds to the brain parenchyma. Paracellular brain uptake of drug compounds is limited by the physical tightness of the endothelium, which is tightly sealed with junction complexes. Transcellular uptake of lipophilic drug compounds is limited by the activity of active efflux pumps in the luminal membrane. As a result, the majority of registered CNS drug compounds are small lipophilic compounds which are not efflux transporter substrates. Small molecule CNS drug development therefore focuses on identifying compounds with CNS target affinity and modifies these in order to optimize lipophilicity and decrease efflux pump interactions. Since efflux pump activity is limiting drug uptake, it has been investigated whether coadministration of drug compounds with efflux pump inhibitors could increase drug uptake. While the concept works to some extent, a lot of challenges have been encountered in terms of obtaining efficient inhibition while avoiding adverse effects.Some CNS drug compounds enter the brain via nutrient transport proteins, an example is the levodopa, a prodrug of Dopamine, which crosses the BBB via the large neutral amino acid transporter LAT1. While carrier-mediated transport of drug compounds may seem attractive, the development of drugs targeting transporters is very challenging, since the compounds should have a good fit to the binding site, while still maintaining their CNS target affinity.Receptor-mediated transport of drug compounds, especially biotherapeutics, conjugated to a receptor-binding ligand has shown some promise, although the amounts transported are rather low. This also holds true for drug-conjugation to cell-penetrating peptides. Due to the low uptake of biotherapeutics, barrier-breaching approaches such as mannitol injections and focused ultrasound have been employed with some success to patient groups with no other treatment options.
Asunto(s)
Barrera Hematoencefálica , Profármacos , Transporte Biológico , Barrera Hematoencefálica/metabolismo , Encéfalo/metabolismo , Proteínas Portadoras , Fármacos del Sistema Nervioso Central/metabolismo , Sistemas de Liberación de Medicamentos , Humanos , Proteínas de Transporte de Membrana/metabolismo , Profármacos/metabolismoRESUMEN
In the development of central nervous system (CNS) drugs, the blood-brain barrier (BBB) restricts many drugs from entering the brain to exert therapeutic effects. Although many novel delivery methods of large molecule drugs have been designed to assist transport, small molecule drugs account for the vast majority of the CNS drugs used clinically. From this perspective, we review studies from the past five years that have sought to modify small molecules to increase brain exposure. Medicinal chemists make it easier for small molecules to cross the BBB by improving diffusion, reducing efflux, and activating carrier transporters. On the basis of their excellent work, we summarize strategies for structural modification of small molecules to improve BBB penetration. These strategies are expected to provide a reference for the future development of small molecule CNS drugs.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Fármacos del Sistema Nervioso Central/metabolismo , Animales , Fármacos del Sistema Nervioso Central/química , Humanos , Enlace de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Estructura Molecular , Permeabilidad , Transcitosis/efectos de los fármacosRESUMEN
Drug delivery to central nervous system (CNS) diseases is very challenging since the presence of the innate blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier that impede drug delivery. Among new strategies to overcome these limitations and successfully deliver drugs to the CNS, nanotechnology-based drug delivery platform, offers potential therapeutic approach for the treatment of some common neurological disorders like Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease. This review aimed to highlight advances in research on the development of nano-based therapeutics for their implications in therapy of CNS disorders. The challenges during clinical translation of nanomedicine from bench to bed side is also discussed.
Asunto(s)
Fármacos del Sistema Nervioso Central/administración & dosificación , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Portadores de Fármacos , Nanomedicina , Nanopartículas , Animales , Barrera Hematoencefálica/metabolismo , Fármacos del Sistema Nervioso Central/química , Fármacos del Sistema Nervioso Central/metabolismo , Enfermedades del Sistema Nervioso Central/metabolismo , Composición de Medicamentos , Desarrollo de Medicamentos , Descubrimiento de Drogas , Humanos , Permeabilidad , Investigación Biomédica TraslacionalRESUMEN
Central nervous system (CNS) disease is one of the most notorious arch-criminals of human health across the world. Although considerable efforts have been devoted to promote the development of CNS drugs, ideal therapeutical effects are yet far from enough. The blood-brain barrier remains a major player that impedes the full potential of CNS therapeutical agents as it blocks the entry of CNS drugs into the brain. The past few decades have witnessed the upspring of prodrug strategies as a promising method to accelerate CNS drug development. The prodrug strategy with the ability to overcome the formidable blood-brain barrier enhances the delivery to the brain and hence improves the effects of the CNS therapeutics. In this Feature Article, we summarize the reported barriers and strategies for CNS therapeutics and spotlight prodrug design strategies to improve the efficiency of crossing the blood-brain barrier.
Asunto(s)
Fármacos del Sistema Nervioso Central/uso terapéutico , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Profármacos/uso terapéutico , Animales , Transporte Biológico/fisiología , Barrera Hematoencefálica/metabolismo , Encéfalo/metabolismo , Fármacos del Sistema Nervioso Central/química , Fármacos del Sistema Nervioso Central/metabolismo , Humanos , Profármacos/química , Profármacos/metabolismoRESUMEN
Despite a relatively low prevalence of primary brain tumors, they continuously attract scientific interest because of the complexity of their treatment due to their location behind the blood-brain barrier. The main challenge in treatment of brain tumors is not the efficacy of the drugs, per se, but the low efficiency of drug delivery to malignant cells. At the core of the problem is the complex structure of the blood-brain barrier. Nowadays, there is evidence supporting the claim that bile acids have the ability to cross the blood-brain barrier. That ability can be exploited by taking a part in novel drug carrier designs. Bile acids represent a drug carrier system as a part of a mixed micelle composition, bilosomes and conjugates with various drugs. This review discusses the current knowledge related to bile acid molecules as drug penetration modifying agents, with the focus on central nervous system antitumor drug delivery.
Asunto(s)
Antineoplásicos/metabolismo , Ácidos y Sales Biliares/metabolismo , Barrera Hematoencefálica/metabolismo , Fármacos del Sistema Nervioso Central/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Neoplasias/metabolismo , Animales , Antineoplásicos/administración & dosificación , Ácidos y Sales Biliares/administración & dosificación , Transporte Biológico/efectos de los fármacos , Transporte Biológico/fisiología , Barrera Hematoencefálica/efectos de los fármacos , Fármacos del Sistema Nervioso Central/administración & dosificación , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/metabolismo , Humanos , Neoplasias/tratamiento farmacológicoRESUMEN
A novel series of multitargeted molecules were designed and synthesized by combining the pharmacological role of cholinesterase inhibitor and antioxidant of steroid as potential ligands for the treatment of Vascular Dementia (VD). The oxygen-glucose deprivation (OGD) model was used to evaluate these molecules, among which the most potent compound ML5 showed the highest activity. Firstly, ML5 showed appropriate inhibition of cholinesterases (ChEs) at orally 15 mg/kg in vivo. The further test revealed that ML5 promoted the nuclear translocation of Nrf2. Furthermore, ML5 has significant neuroprotective effect in vivo model of bilateral common carotid artery occlusion (BCCAO), significantly increasing the expression of Nrf2 protein in the cerebral cortex. In the molecular docking research, we predicted the ML5 combined with hAChE and Keap1. Finally, compound ML5 displayed normal oral absorption and it was nontoxic at 500 mg/kg, po, dose. We can draw the conclusion that ML5 could be considered as a new potential compound for VD treatment.
Asunto(s)
Fármacos del Sistema Nervioso Central/uso terapéutico , Inhibidores de la Colinesterasa/uso terapéutico , Demencia Vascular/tratamiento farmacológico , Diosgenina/análogos & derivados , Diosgenina/uso terapéutico , Sustancias Protectoras/uso terapéutico , Acetilcolinesterasa/metabolismo , Animales , Supervivencia Celular/efectos de los fármacos , Fármacos del Sistema Nervioso Central/síntesis química , Fármacos del Sistema Nervioso Central/metabolismo , Fármacos del Sistema Nervioso Central/toxicidad , Inhibidores de la Colinesterasa/síntesis química , Inhibidores de la Colinesterasa/metabolismo , Inhibidores de la Colinesterasa/toxicidad , Diosgenina/metabolismo , Diosgenina/toxicidad , Humanos , Proteína 1 Asociada A ECH Tipo Kelch/metabolismo , Aprendizaje/efectos de los fármacos , Masculino , Memoria/efectos de los fármacos , Ratones Endogámicos ICR , Simulación del Acoplamiento Molecular , Factor 2 Relacionado con NF-E2/metabolismo , Neuroprotección/efectos de los fármacos , Sustancias Protectoras/síntesis química , Sustancias Protectoras/metabolismo , Sustancias Protectoras/toxicidad , Unión Proteica , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismoRESUMEN
Delivery of compounds to the brain is critical for the development of effective treatment therapies of multiple central nervous system diseases. Recently a novel insect-based brain uptake model was published utilizing a locust brain ex vivo system. The goal of our study was to develop a priori, in silico cheminformatic models to describe brain uptake in this insect model, as well as evaluate the predictive ability. The machine learning program Orange® was used to evaluate several machine learning (ML) models on a published data set of 25 known drugs, with in vitro data generated by a single laboratory group to reduce inherent inter-laboratory variability. The ML models included in this study were linear regression (LR), support vector machines (SVN), k-nearest neighbor (kNN) and neural nets (NN). The quantitative structure-property relationship models were able to correlate experimental logCtot (concentration of compound in brain) and predicted brain uptake of r2 > 0.5, with the descriptors log(P*MW-0.5) and hydrogen bond donor used in LR, SVN and KNN, while log(P*MW-0.5) and total polar surface area (TPSA) descriptors used in the NN models. Our results indicate that the locust insect model is amenable to data mining chemoinformatics and in silico model development in CNS drug discovery pipelines.
Asunto(s)
Encéfalo/metabolismo , Fármacos del Sistema Nervioso Central/metabolismo , Animales , Fármacos del Sistema Nervioso Central/química , Quimioinformática , Bases de Datos de Compuestos Químicos/estadística & datos numéricos , Saltamontes/metabolismo , Modelos Lineales , Modelos Biológicos , Redes Neurales de la Computación , Máquina de Vectores de SoporteRESUMEN
The initial exploration using pharmacological tools of the role of adenosine receptors in the brain, concluded that adenosine released as such acted on A1R to inhibit excitability and glutamate release from principal neurons throughout the brain and that adenosine A2A receptors (A2AR) were striatal-'specific' receptors controlling dopamine D2R. This indicted A1R as potential controllers of neurodegeneration and A2AR of psychiatric conditions. Global knockout of these two receptors questioned the key role of A1R and instead identified extra-striatal A2AR as robust controllers of neurodegeneration. Furthermore, transgenic lines with altered metabolic sources of adenosine revealed a coupling of ATP-derived adenosine to activate A2AR and a role of A1R as a hurdle to initiate neurodegeneration. Additionally, cell-selective knockout of A2AR unveiled the different roles of A2AR in different cell types (neurons/astrocytes) in different portions of the striatal circuits (dorsal versus lateral) and in different brain areas (hippocampus/striatum). Finally, a new transgenic mouse line with deletion of all adenosine receptors seems to indicate a major allostatic rather than homeostatic role of adenosine and may allow isolating P2R-mediated responses to unravel their role in the brain, a goal close to heart of Geoffrey Burnstock, to whom we affectionately dedicate this review.
Asunto(s)
Adenosina/administración & dosificación , Adenosina/metabolismo , Encéfalo/metabolismo , Fármacos del Sistema Nervioso Central/administración & dosificación , Fármacos del Sistema Nervioso Central/metabolismo , Receptores Purinérgicos P1/metabolismo , Animales , Encéfalo/efectos de los fármacos , Ratones , Ratones Noqueados , Ratones TransgénicosRESUMEN
AIM: To generate and validate predictive models for blood-brain permeation (BBB) of CNS molecules using the QSPR approach. BACKGROUND: Prediction of molecules crossing BBB remains a challenge in drug delivery. Predictive models are designed for the evaluation of a set of preclinical drugs which may serve as alternatives for determining BBB permeation by experimentation. OBJECTIVE: The objective of the present study was to generate QSPR models for the permeation of CNS molecules across BBB and its validation using existing in-house leads. METHODS: The present study envisaged the determination of the set of molecular descriptors which are considered significant correlative factors for BBB permeation property. Quantitative Structure- Property Relationship (QSPR) approach was followed to describe the correlation between identified descriptors for 45 molecules and highest, moderate and least BBB permeation data. The molecular descriptors were selected based on drug-likeness, hydrophilicity, hydrophobicity, polar surface area, etc. of molecules that served the highest correlation with BBB permeation. The experimental data in terms of log BB were collected from available literature, subjected to 2D-QSPR model generation using a regression analysis method like Multiple Linear Regression (MLR). RESULTS: The best QSPR model was Model 3, which exhibited regression coefficient as R2= 0.89, F = 36; Q2= 0.7805 and properties such as polar surface area, hydrophobic hydrophilic distance, electronegativity, etc., which were considered key parameters in the determination of the BBB permeability. The developed QSPR models were validated with in-house 1,5-benzodiazepines molecules and correlation studies were conducted between experimental and predicted BBB permeability. CONCLUSION: The QSPR model 3 showed predictive results that were in good agreements with experimental results for blood-brain permeation. Thus, this model was found to be satisfactory in achieving a good correlation between selected descriptors and BBB permeation for benzodiazepines and tricyclic compounds.
Asunto(s)
Benzodiazepinas/química , Benzodiazepinas/metabolismo , Barrera Hematoencefálica/metabolismo , Fármacos del Sistema Nervioso Central/química , Fármacos del Sistema Nervioso Central/metabolismo , Simulación por Computador , Benzodiazepinas/farmacología , Barrera Hematoencefálica/efectos de los fármacos , Fármacos del Sistema Nervioso Central/farmacología , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Relación Estructura-Actividad CuantitativaRESUMEN
Among the most devastating disorders of our time, neurologic and psychiatric diseases combine to cause more disability than any other disease area. One of the key objectives within the medicinal chemistry discipline is to design molecules that penetrate into the target tissue. The objective of tissue specificity can be to gain or restrict drug access to the compartment of interest. This article briefly reviews the progress of CNS drug discovery over the past few decades. Included are the most recent efforts to harness structural and physicochemical properties assessment coupled with the impact of efflux transporters in determining brain penetration and the translation from rodent to human brain tissue targeting.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Encéfalo/metabolismo , Fármacos del Sistema Nervioso Central/metabolismo , Animales , Línea Celular , Descubrimiento de Drogas , HumanosRESUMEN
A library of novel anilide and benzylamide derivatives of ω-(4-(2-methoxyphenyl)piperazin-1-yl)alkanoic acids as combined 5-HT1A/5-HT7 receptor ligands and phosphodiesterase PDE4B/PDE7A inhibitors was designed using a structure-based drug design approach. The in vitro studies of 33 newly synthesized compounds (7-39) allowed us to identify 22 as the most promising multifunctional 5-HT1A/5-HT7 receptor antagonist (5-HT1AKi = 8 nM, Kb = 0.04 nM; 5-HT7Ki = 451 nM, Kb = 460 nM) with PDE4B/PDE7A inhibitory activity (PDE4B IC50 = 80.4 µM; PDE7A IC50 = 151.3 µM). Compound 22 exerted a very good ability to passively penetrate through biological membranes and a high metabolic stability in vitro. Moreover, the pharmacological evaluation of 22 showed its procognitive and antidepressant properties in rat behavioral tests. Compound 22 at a dose of 3 mg/kg (i.p.) significantly reversed MK-801-induced episodic memory deficits in the novel object recognition test, while at a dose of 10 mg/kg (i.p.) reduced the immobility time of animals (by about 34%) in the forced swimming test. The antidepressant-like effect produced by compound 22 was stronger than that of escitalopram used as a reference drug. This study opens a new perspective in the search for efficacious drugs for the treatment of cognitive and depressive disorders.
Asunto(s)
Anilidas/farmacología , Fármacos del Sistema Nervioso Central/farmacología , Inhibidores de Fosfodiesterasa 4/farmacología , Piperazinas/farmacología , Antagonistas del Receptor de Serotonina 5-HT1/farmacología , Anilidas/síntesis química , Anilidas/metabolismo , Animales , Células CHO , Fármacos del Sistema Nervioso Central/síntesis química , Fármacos del Sistema Nervioso Central/metabolismo , Cricetulus , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 7/antagonistas & inhibidores , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 7/metabolismo , Células HEK293 , Humanos , Masculino , Microsomas Hepáticos/metabolismo , Simulación del Acoplamiento Molecular , Estructura Molecular , Prueba de Campo Abierto/efectos de los fármacos , Inhibidores de Fosfodiesterasa 4/síntesis química , Inhibidores de Fosfodiesterasa 4/metabolismo , Piperazinas/síntesis química , Piperazinas/metabolismo , Unión Proteica , Ratas Wistar , Receptor de Serotonina 5-HT1A/metabolismo , Receptores de Serotonina/metabolismo , Antagonistas del Receptor de Serotonina 5-HT1/síntesis química , Antagonistas del Receptor de Serotonina 5-HT1/metabolismo , Células Sf9 , Relación Estructura-ActividadRESUMEN
Now, it has been evidenced that Covid19 (SARS-CoV-2) infects the brain tissues. Along with this, a challenge has been raised for research professionals to find effective drugs for its treatment since the recent spread of this virus from Wuhan, China. Targeting the treatment of brain infection, it has also been a challenge that the clinical drug should have good CNS penetration ability to cross the blood-brain barrier.
Asunto(s)
Betacoronavirus , Barrera Hematoencefálica/metabolismo , Encéfalo/metabolismo , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/metabolismo , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/metabolismo , Adenosina Monofosfato/administración & dosificación , Adenosina Monofosfato/análogos & derivados , Adenosina Monofosfato/metabolismo , Alanina/administración & dosificación , Alanina/análogos & derivados , Alanina/metabolismo , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/metabolismo , Antivirales/administración & dosificación , Antivirales/metabolismo , Betacoronavirus/efectos de los fármacos , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/virología , Encéfalo/efectos de los fármacos , COVID-19 , Fármacos del Sistema Nervioso Central/administración & dosificación , Fármacos del Sistema Nervioso Central/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Humanos , Metilprednisolona/administración & dosificación , Metilprednisolona/metabolismo , Pandemias , SARS-CoV-2 , Resultado del TratamientoRESUMEN
Antibody-based therapeutics targeting CNS antigens emerge as promising treatments in neurology. However, access to the CNS is limited by the blood-brain barrier. We examined the effects of a neurite growth-enhancing anti-Nogo A antibody therapy following 3 routes of administration-intrathecal (i.t.), intravenous (i.v.), and subcutaneous (s.c.)-after large photothrombotic strokes in adult rats. Intrathecal treatment of full-length IgG anti-Nogo A antibodies enhanced recovery of the grasping function, but intravenous or subcutaneous administration had no detectable effect in spite of large amounts of antibodies in the peripheral circulation. Thus, in contrast to intravenous and subcutaneous delivery, intrathecal administration is an effective and reliable way to target CNS antigens. Our data reveal that antibody delivery to the CNS is far from trivial. While intrathecal application is feasible and guarantees defined antibody doses in the effective range for a biological function, the identification and establishment of easier routes of administration remains an important task to facilitate antibody-based future therapies of CNS disorders.
Asunto(s)
Anticuerpos/administración & dosificación , Fármacos del Sistema Nervioso Central/administración & dosificación , Sistemas de Liberación de Medicamentos/métodos , Proteínas Nogo/antagonistas & inhibidores , Accidente Cerebrovascular/tratamiento farmacológico , Administración Intravenosa , Animales , Anticuerpos/metabolismo , Fármacos del Sistema Nervioso Central/metabolismo , Femenino , Inyecciones Espinales , Inyecciones Subcutáneas , Proteínas Nogo/metabolismo , Ratas , Ratas Long-Evans , Accidente Cerebrovascular/diagnóstico por imagen , Accidente Cerebrovascular/metabolismo , Resultado del TratamientoRESUMEN
Lipophilic weak base therapeutic agents, termed lysosomotropic drugs (LDs), undergo marked sequestration and concentration within lysosomes, hence altering lysosomal functions. This lysosomal drug entrapment has been described as luminal drug compartmentalization. Consistent with our recent finding that LDs inflict a pH-dependent membrane fluidization, we herein demonstrate that LDs undergo intercalation and concentration within lysosomal membranes. The latter was revealed experimentally and computationally by (a) confocal microscopy of fluorescent compounds and drugs within lysosomal membranes, and (b) molecular dynamics modeling of the pH-dependent membrane insertion and accumulation of an assortment of LDs, including anticancer drugs. Based on the multiple functions of the lysosome as a central nutrient sensory hub and a degradation center, we discuss the molecular mechanisms underlying the alteration of morphology and impairment of lysosomal functions as consequences of LDs' intercalation into lysosomes. Our findings bear important implications for drug design, drug induced lysosomal damage, diseases and pertaining therapeutics.
Asunto(s)
Fármacos del Sistema Nervioso Central/farmacología , Sustancias Intercalantes/farmacología , Lisosomas/efectos de los fármacos , Antineoplásicos/farmacología , Línea Celular Tumoral , Fármacos del Sistema Nervioso Central/análisis , Fármacos del Sistema Nervioso Central/metabolismo , Resistencia a Antineoplásicos/efectos de los fármacos , Humanos , Interacciones Hidrofóbicas e Hidrofílicas/efectos de los fármacos , Sustancias Intercalantes/análisis , Sustancias Intercalantes/metabolismo , Membranas Intracelulares , Lisosomas/metabolismo , Simulación de Dinámica Molecular , Preparaciones Farmacéuticas/análisis , Preparaciones Farmacéuticas/metabolismo , Secuestrantes/metabolismoRESUMEN
The blood-brain barrier (BBB) protects the brain from the toxic side effects of drugs and exogenous molecules. However, it is crucial that medications developed for neurological disorders cross into the brain in therapeutic concentrations. Understanding the BBB interaction with drug molecules based on physicochemical property space can guide effective and efficient drug design. An algorithm, designated "BBB Score", composed of stepwise and polynomial piecewise functions, is herein proposed for predicting BBB penetration based on five physicochemical descriptors: number of aromatic rings, heavy atoms, MWHBN (a descriptor comprising molecular weight, hydrogen bond donor, and hydrogen bond acceptors), topological polar surface area, and pKa. On the basis of statistical analyses of our results, the BBB Score outperformed (AUC = 0.86) currently employed MPO approaches (MPO, AUC = 0.61; MPO_V2, AUC = 0.67). Initial evaluation of physicochemical property space using the BBB Score is a valuable addition to currently available drug design algorithms.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Fármacos del Sistema Nervioso Central/metabolismo , Biología Computacional , Fármacos del Sistema Nervioso Central/farmacología , Bases de Datos Farmacéuticas , Diseño de Fármacos , PermeabilidadRESUMEN
BACKGROUND: Over fifty percent of drugs being used clinically are chiral and 90% of them are racemates. Unfortunately, they have both adverse and beneficial effects on body systems. METHODS: Because of the erratic effects of chiral compounds on body functional systems, literature search was carried out with a view to identify CNS chiral drugs, their clinical advantages and disadvantages, unique physicochemical properties and structural modifications into safer drugs. RESULTS: Findings have shown that majority of CNS and non-CNS acting drugs have chiral functional groups that may occur as either dextrorotatory (clockwise) or levorotatory (anticlockwise) or racemates which are inert. Sometimes, the enantiomers (optical isomers) could undergo keto-enol tautomerism, appearing in either acidic or basic or inert form. Chiral CNS acting drugs have agonistic and antagonistic effects, clinical advantages, disadvantages, and special clinical applications, possible modifications for better therapeutic effects and possible synthesis of more potent drugs from racemates. Clockwise chirality may be more effective and safer than the drugs with anticlockwise chirality. When chiral drugs are in racemate state they become inert and may be safer than when they are single. Also, diastereoisomers may be more dangerous than stereoisomers. CONCLUSION: Therefore, chiral compounds should be adequately studied in lab rodents and primates, and their mechanisms of actions should be comprehensively understood before being used in clinical setting. Since many of them are toxic, their use should be based on principle of individualized medicine. Their molecular weights, functional groups, metabolites, polymers and stereoisomers could be valuable tools for their modifications.